Health Care & Life Sciences » Biotechnology | Eiger BioPharmaceuticals Inc.

Eiger BioPharmaceuticals Inc. | Ownership

Companies that own Eiger BioPharmaceuticals Inc.

Name
Shares Held
% Shares Out
Change In Shares
% of Assets
As of Date
Jennison Associates LLC
1,256,501
8.84%
606,361
0.01%
06/30/2018
Ecor1 Capital LLC
1,039,500
7.31%
1,039,500
1.39%
06/30/2018
Adage Capital Management LP
682,200
4.8%
682,200
0.02%
06/30/2018
Prosight Management LP
438,422
3.08%
-92,426
3.87%
06/30/2018
The Vanguard Group, Inc.
427,330
3.01%
150,637
0%
06/30/2018
683 Capital Management LLC
295,285
2.08%
100,000
0.43%
06/30/2018
GMT Capital Corp.
283,542
2%
283,542
0.08%
06/30/2018
Renaissance Technologies LLC
230,229
1.62%
66,200
0%
06/30/2018
BlackRock Fund Advisors
185,752
1.31%
125,878
0%
06/30/2018
Perceptive Advisors LLC
157,679
1.11%
0
0.05%
06/30/2018

About Eiger BioPharmaceuticals

View Profile
Address
2155 Park Boulevard
Palo Alto California 94306
United States
Employees -
Website http://www.eigerbio.com
Updated 07/08/2019
Eiger BioPharmaceuticals, Inc is a clinical-stage biopharmaceutical company, which engages in the development and commercialization of targeted therapies for orphan diseases. It focuses on product candidates for the treatment of orphan diseases such as Sarasar, Pegylated Interferon Lambda, Exendin 9-39, and Ubenimex. The company was founded by David A.

StatInvestor

Privacy Policy
Feedback

© 2024 StatInvestor All Rights Reserved.